83942-13-6

Basic information

• Product Name: 4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine
• Synonyms: 4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine;4-Chloro-6,7-dihydro-5H-cyclopentapyrimidine;4-chloro-6,7-dihydro-5H-cyclopenta[e]pyrimidine
• CAS NO: 83942-13-6
• Molecular Formula: C₇H₇ClN₂
• Molecular Weight: 154.599
• Mol File: 83942-13-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 196-197 °C
• Boiling Point: 271.7 °C at 760 mmHg
• Flash Point: 144.3 °C
• Appearance: /
• Density: 1.322 g/cm³
• Vapor Pressure: 0.0106mmHg at 25°C
• Refractive Index: 1.59
• PKA: 1.07±0.20(Predicted)
• CAS DataBase Reference: 4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine(83942-13-6)
• EPA Substance Registry System: 4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine(83942-13-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 83942-13-6(Hazardous Substances Data)

Usage

General Description

4-Chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine is a chemical compound that belongs to the class of cyclopenta[d]pyrimidines. Its molecular formula is C6H7ClN2, and it has a molecular weight of 148.59 g/mol. 4-Chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine is a heterocyclic organic compound with a five-membered cyclopenta-2,4-dienyl ring fused to a pyrimidine ring. It is utilized in various fields, including pharmaceuticals and agrochemicals. Additionally, it is a building block for the synthesis of various biologically active compounds due to its diverse reactivity and stability.

InChI:InChI=1/C7H7ClN2/c8-7-5-2-1-3-6(5)9-4-10-7/h4H,1-3H2

Upstream product

• 5661-01-8 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol 
• 10472-24-9 methyl 2-oxocyclopentane-1-carboxylate 
• 52909-60-1 2aminocyclopentene-1-carboxylic acid methyl ester 
• 1452392-78-7 2-formamidocyclopentene-1-carboxylic acid methyl ester 
• 5661-01-8 6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one 
• 35563-27-0 2-mercapto-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol 
• 2941-23-3 2-amino-1-cyanocyclopentene 
• 111-69-3 hexanedinitrile 

Downstream Products

• 6014-10-4 6H-Cyclopentenopyrimidin-7-thion 
• 5661-00-7 5H-6,7-dihydrocyclopentapyrimidine 
• 26979-06-6 4-amino-6,7-dihydro-5H-cyclopenta[1,2-d]pyrimidine 
• 158973-38-7 N-(5,6-dihydro-7H-cyclopenta[d]pyrimidin-4-yl)-4-[(1-benzyl-4-piperidinyliden)acetyl]aniline 
• 85089-92-5 4-(4-Chloroanilino)-6,7-dihydro-5H-cyclopenta[d]pyrimidine 
• 83942-29-4 4-[2-(2-methyl-4-n-pentylphenoxy)ethylamino]-5,6-trimethylenepyrimidine 
• 1452392-88-9 N-(4-methoxyphenyl)-N-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride 
• 1452392-83-4 N-methyl-N-(4-(methylthio)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 
• 1452392-81-2 N-methyl-N-p-tolyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 
• 1001270-39-8 tert-butyl 2-(4-chlorophenyl)-3-(4-(7-hydroxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate 

Relevant articles and documents

Cyclopenta [d] pyrimidine compound, pharmaceutically acceptable salt, solvate or prodrug thereof and application

The invention discloses a cyclopenta [d] pyrimidine compound, a pharmaceutically acceptable salt, solvate or prodrug thereof, and an application of the cyclopenta [d] pyrimidine compound, the pharmaceutically acceptable salt, the solvate or the prodrug. T

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I). Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.